These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 11956450)
41. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697 [TBL] [Abstract][Full Text] [Related]
42. Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. Miller JA; Pramanik B; Gilhooly P South Med J; 1999 Jun; 92(6):615-7. PubMed ID: 10372857 [TBL] [Abstract][Full Text] [Related]
43. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing]. Wolff H; Kunte C MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972 [TBL] [Abstract][Full Text] [Related]
44. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. Overstreet JW; Fuh VL; Gould J; Howards SS; Lieber MM; Hellstrom W; Shapiro S; Carroll P; Corfman RS; Petrou S; Lewis R; Toth P; Shown T; Roy J; Jarow JP; Bonilla J; Jacobsen CA; Wang DZ; Kaufman KD J Urol; 1999 Oct; 162(4):1295-300. PubMed ID: 10492183 [TBL] [Abstract][Full Text] [Related]
45. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies. Whiting DA Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540 [TBL] [Abstract][Full Text] [Related]
48. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Lam JS; Romas NA; Lowe FC Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947 [TBL] [Abstract][Full Text] [Related]
49. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group Eur J Dermatol; 2002; 12(1):38-49. PubMed ID: 11809594 [TBL] [Abstract][Full Text] [Related]
50. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. Foley SJ; Soloman LZ; Wedderburn AW; Kashif KM; Summerton D; Basketter V; Holmes SA J Urol; 2000 Feb; 163(2):496-8. PubMed ID: 10647664 [TBL] [Abstract][Full Text] [Related]
51. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Roehrborn CG; Lee M; Meehan A; Waldstreicher J; Urology; 2003 Nov; 62(5):894-9. PubMed ID: 14624915 [TBL] [Abstract][Full Text] [Related]
52. Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study. Vaarala MH; Lukkarinen O; Marttila T; Kyllönen AP; Porvari KS; Vihko PT World J Urol; 2000 Dec; 18(6):406-10. PubMed ID: 11204259 [TBL] [Abstract][Full Text] [Related]
53. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J; Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651 [TBL] [Abstract][Full Text] [Related]
54. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Borst SE; Yarrow JF; Conover CF; Nseyo U; Meuleman JR; Lipinska JA; Braith RW; Beck DT; Martin JS; Morrow M; Roessner S; Beggs LA; McCoy SC; Cannady DF; Shuster JJ Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E433-42. PubMed ID: 24326421 [TBL] [Abstract][Full Text] [Related]
55. [Gynecomastia and finasteride]. Schmutz JL; Barbaud A; Trechot P Ann Dermatol Venereol; 2001 May; 128(5):691. PubMed ID: 11427816 [No Abstract] [Full Text] [Related]
56. Effect of testosterone treatment on bone mineral density in men over 65 years of age. Snyder PJ; Peachey H; Hannoush P; Berlin JA; Loh L; Holmes JH; Dlewati A; Staley J; Santanna J; Kapoor SC; Attie MF; Haddad JG; Strom BL J Clin Endocrinol Metab; 1999 Jun; 84(6):1966-72. PubMed ID: 10372695 [TBL] [Abstract][Full Text] [Related]
58. [Finasteride. A new 5 alpha reductase inhibitor registered for treatment of benign prostatic hypertrophy with the purpose of avoiding or postponing surgery]. Hansen BJ; Hvidt V Ugeskr Laeger; 1993 Dec; 155(50):4110-2. PubMed ID: 7505966 [No Abstract] [Full Text] [Related]
59. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. Bird ST; Brophy JM; Hartzema AG; Delaney JA; Etminan M J Urol; 2013 Nov; 190(5):1811-4. PubMed ID: 23665270 [TBL] [Abstract][Full Text] [Related]
60. Bone density is normal in male rats treated with finasteride. Rosen HN; Tollin S; Balena R; Middlebrooks VL; Moses AC; Yamamoto M; Zeind AJ; Greenspan SL Endocrinology; 1995 Apr; 136(4):1381-7. PubMed ID: 7895648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]